A new episode focusses on the recently published 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.

This importnat guideline provides practical advice for rheumatologists navigating the complexities of managing patients with both inflammatory arthritis like rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis,and a past cancer diagnosis.

In this episode, we'll delve into key aspects of these recommendations, including:

• The importance of assessing the individualized risk of cancer recurrence,

• The necessity of co-management with oncology specialists and shared decision-making with patients,

• The recommendation to initiate appropriate targeted antirheumatic treatment without delay in patients with cancer in remission,

• Guidance on managing patients with active IA and a malignancy that is not in remission.

This episode is for rheumatologists, oncologists, primary care physicians, and anyone involved in the care of patients with inflammatory arthritis and a history of cancer. Understanding these 2024 EULAR points to consider can help enhance therapeutic decision-making and optimize patient outcomes.

This episode is based to the publication Sebbag E, et al.Ann Rheum Dis 2025;84:388-397

and was developed with NotebookLM.